prescription spending high-cost specialty drugs genetic and metabolic markers Related: FDA fast-tracking gene therapies

A prescription for wasteful spending

Using metabolic fingerprints to target medication therapy

Real world impact of pharmacogenetics testing

Journal of Medical Economics
Jennifer Fuhrmann-Berger Jennifer Fuhrmann-Berger, Pharm.D., is senior vice president of clinical services at BeneCard PBF, a pharmacy benefit manager (PBM) based in Mechanicsburg, Pennsylvania.
NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.